We are live on !
Find out more
Blue Owl Capital Holdings Portfolio holdings
AUM
$548M
Turnover
33.33%
1-Year Est. Return
35.34%
This Fund
S&P 500
This Quarter Est. Return
-11.58%
1 Year Est. Return
+35.34%
3 Year Est. Return
+118.27%
5 Year Est. Return
+18.83%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$117M
(-18%)
Cap. Flow
+$26.5M
Cap. Flow % of AUM
Cap. Flow %
4.83%
Top 10 Holdings %
Top 10 Hldgs %
77.43%
Holding
93
New
17
Increased
8
Reduced
15
Closed
14
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
1.2
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1.2
years
Top 10 Avg Time Held Equity only
1.2
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LTGO
Latigo Biotherapeutics
LTGO
|
+$75.9M |
| 2 |
ETRA
Electra Therapeutics
ETRA
|
+$32.1M |
| 3 |
Obsidian Therapeutics
OBX
|
+$29M |
| 4 |
Aktis Oncology
AKTS
|
+$6.66M |
| 5 |
Veradermics
MANE
|
+$4.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$65.8M |
| 2 |
Capital One
COF
|
+$24M |
| 3 |
EyePoint
EYPT
|
+$10.9M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$6.82M |
| 5 |
Dell
DELL
|
+$6.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.1% |
| 2 | Industrials | 26.97% |
| 3 | Financials | 8.43% |
| 4 | Technology | 4.56% |
| 5 | Consumer Discretionary | 1.89% |
Similar funds
CIM
VHMC
Blue Owl Capital Holdings's Q3 2026 Portfolio in Review
As of Q3 2026, Blue Owl Capital Holdings held 93 positions worth $548M, down 18% from $665M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Blue Owl Capital Holdings deployed $26.5M of net new capital in Q3 2026, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Latigo Biotherapeutics: 3,596,780 shares worth $60.1M.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 44% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was SpaceX, an estimated $65.8M trimmed.
- Blue Owl Capital Holdings's largest Q3 2026 buy was Latigo Biotherapeutics: 3,596,780 shares worth $60.1M.
- Blue Owl Capital Holdings added most to Aktis Oncology in Q3 2026, an estimated $6.66M increase.
- Blue Owl Capital Holdings's biggest Q3 2026 reduction was SpaceX, cutting an estimated $65.8M.
- Blue Owl Capital Holdings fully exited Capital One in Q3 2026, selling an estimated $24M.
- Blue Owl Capital Holdings's ten largest holdings make up 77% of its $548M portfolio in Q3 2026.
- Blue Owl Capital Holdings opened 17 new positions and closed 14 in Q3 2026.
- Blue Owl Capital Holdings's portfolio value fell 18% quarter-over-quarter to $548M.
Based on Blue Owl Capital Holdings's 13F filing for Q3 2026, filed 13 Nov 2026.